Skip to ContentSkip to Navigation
University of Groningenfounded in 1614  -  top 100 university
About us Practical matters How to find us prof. dr. T. van Meerten
University Medical Center Groningen

prof. dr. T. van Meerten

No picture available
E-mail:
t.van.meerten umcg.nl

Publications

Author Correction: Whole-body CD8 + T-cell PET imaging in patients with large B-cell lymphoma before and during CD19-directed CAR T-cell therapy: a phase 2 study.

Impact of Rituximab Maintenance on Survival in Patients with Mantle Cell Lymphoma; a Population-based Cohort Study

Multi-omic profiling and preclinical efficacy of fratricide-driven, unedited CD7 CAR-T cells in T-cell leukemia

1764 Decrease of metabolic active tumour volume of target- and unintentionally irradiated lesions after bridging radiotherapy prior to CAR T-cell therapy

Brexucabtagene autoleucel versus allogeneic hematopoietic cell transplantation in relapsed and refractory mantle cell lymphoma

Higher heliosâș treg levels pre- and post-CAR T infusion are associated with inferior outcomes in patients with LBCL

Ibrutinib plus venetoclax in relapsed or refractory mantle cell lymphoma (SYMPATICO): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study

K12-ligand-based CAR T cell therapy for CD7-positive T cell malignancies

Patients With Relapsed Large B-Cell Lymphoma After 12 Months Have a Similarly Poor Prognosis to Those Relapsing Within 12 Months

Population-based validation of the CAR-HEMATOTOX for hematotoxicity, infections and survival after CART in R/R LBCL

Press/media

Je eigen bloedcellen als medicijn tegen een auto-immuunziekte of bloedkanker

Dr van Meerten on the Optimal Use of Brexu-Cel in BTK Inhibitor–Naive MCL

Dr van Meerten on the Role of Brexu-Cel in High-Risk MCL

Prof. Tom van Meerten (UMCG) over beta-hydroxybutyraat en CAR T-cel fitness

Subsidie voor onderzoek CAR-T-cellen voor mensen met multipel myeloom

Onderzoek naar effect CAR T-cellen bij terugkerende beenmergkanker krijgt subsidie

Gronings UMC gaat met overheidssubsidie zelf een prijzig buitenlands kankermedicijn maken

16,5 miljoen subsidie voor onderzoek CAR T-cellen bij beenmergkanker

Wat is de potentie van CAR-Tceltherapie bij terugkerende beenmergkanker?

UMCG krijgt miljoenen voor nieuwe behandeling van beenmergkanker: 'Je wint tijd'